CL2012000428A1 - Uso de un aerosol de una solucion de levofloxacina u ofloxacina para reducir la tasa de exacerbaciones agudas de un transtorno pulmonar seleccionado de epoc y bronquitis cronica. - Google Patents

Uso de un aerosol de una solucion de levofloxacina u ofloxacina para reducir la tasa de exacerbaciones agudas de un transtorno pulmonar seleccionado de epoc y bronquitis cronica.

Info

Publication number
CL2012000428A1
CL2012000428A1 CL2012000428A CL2012000428A CL2012000428A1 CL 2012000428 A1 CL2012000428 A1 CL 2012000428A1 CL 2012000428 A CL2012000428 A CL 2012000428A CL 2012000428 A CL2012000428 A CL 2012000428A CL 2012000428 A1 CL2012000428 A1 CL 2012000428A1
Authority
CL
Chile
Prior art keywords
levofloxacin
ofloxacin
copd
rate
solution
Prior art date
Application number
CL2012000428A
Other languages
English (en)
Inventor
Elizabeth E Morgan
Michael N Dudley
David C Griffith
Neil Berkley
Jeffrey S Loutit
Keith A Bostian
Sanjay Sethi
Original Assignee
Mpex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43607264&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012000428(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mpex Pharmaceuticals Inc filed Critical Mpex Pharmaceuticals Inc
Publication of CL2012000428A1 publication Critical patent/CL2012000428A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Método para reducir la tasa de exacerbaciones agudas de un trastorno pulmonar seleccionado de epoc y bronquitis crónica por medio de la administración en aerosol de una solución de levofloxacino u ofloxacino
CL2012000428A 2009-08-19 2012-02-17 Uso de un aerosol de una solucion de levofloxacina u ofloxacina para reducir la tasa de exacerbaciones agudas de un transtorno pulmonar seleccionado de epoc y bronquitis cronica. CL2012000428A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23531909P 2009-08-19 2009-08-19
US24074909P 2009-09-09 2009-09-09
US24922809P 2009-10-06 2009-10-06

Publications (1)

Publication Number Publication Date
CL2012000428A1 true CL2012000428A1 (es) 2012-09-28

Family

ID=43607264

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012000428A CL2012000428A1 (es) 2009-08-19 2012-02-17 Uso de un aerosol de una solucion de levofloxacina u ofloxacina para reducir la tasa de exacerbaciones agudas de un transtorno pulmonar seleccionado de epoc y bronquitis cronica.

Country Status (13)

Country Link
US (1) US20120237564A1 (es)
EP (1) EP2467138A4 (es)
JP (1) JP2013502416A (es)
KR (1) KR20120103561A (es)
CN (1) CN102711760A (es)
AU (1) AU2010284678A1 (es)
BR (1) BR112012003453A2 (es)
CA (1) CA2770355A1 (es)
CL (1) CL2012000428A1 (es)
IL (1) IL218148A0 (es)
MX (1) MX2012002091A (es)
RU (1) RU2012108962A (es)
WO (1) WO2011022075A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8546423B2 (en) 2005-05-18 2013-10-01 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
NZ592717A (en) * 2008-10-07 2013-03-28 Mpex Pharmaceuticals Inc Aerosol fluoroquinolone formulations for improved pharmacokinetics comprising levofloxacin or ofloxacin and a di- or trivalent cation
PT2346509T (pt) 2008-10-07 2020-08-05 Horizon Orphan Llc Inalação de levofloxacina para redução da inflamação pulmonar
RU2563809C2 (ru) 2009-09-04 2015-09-20 Мпекс Фармасьютикалс, Инк. Применение левофлоксацина в форме аэрозоля для лечения муковисцидоза
US20160068527A1 (en) * 2013-04-09 2016-03-10 Cresset Biomolecular Discovery Ltd. The Treatment of Inflammatory Disorders
CA3109823A1 (en) * 2018-08-22 2020-02-27 Avalyn Pharma Inc. Specially formulated compositions of inhaled nintedanib and nintedanib salts

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1901749T3 (en) * 2005-05-18 2016-10-24 Raptor Pharmaceuticals Inc Aerosolized fluoroquinolones AND USES THEREOF
US7838532B2 (en) * 2005-05-18 2010-11-23 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
RU2008136460A (ru) * 2006-02-10 2010-03-20 Пари Фарма ГмбХ (DE) Фармацевтический аэрозоль
NZ592717A (en) * 2008-10-07 2013-03-28 Mpex Pharmaceuticals Inc Aerosol fluoroquinolone formulations for improved pharmacokinetics comprising levofloxacin or ofloxacin and a di- or trivalent cation
PT2346509T (pt) * 2008-10-07 2020-08-05 Horizon Orphan Llc Inalação de levofloxacina para redução da inflamação pulmonar

Also Published As

Publication number Publication date
KR20120103561A (ko) 2012-09-19
IL218148A0 (en) 2012-06-28
WO2011022075A1 (en) 2011-02-24
CA2770355A1 (en) 2011-02-24
AU2010284678A1 (en) 2012-02-23
CN102711760A (zh) 2012-10-03
JP2013502416A (ja) 2013-01-24
BR112012003453A2 (pt) 2019-09-24
US20120237564A1 (en) 2012-09-20
EP2467138A1 (en) 2012-06-27
MX2012002091A (es) 2012-07-03
RU2012108962A (ru) 2013-09-27
EP2467138A4 (en) 2013-11-06

Similar Documents

Publication Publication Date Title
CL2012000428A1 (es) Uso de un aerosol de una solucion de levofloxacina u ofloxacina para reducir la tasa de exacerbaciones agudas de un transtorno pulmonar seleccionado de epoc y bronquitis cronica.
EA201391392A1 (ru) Синтетические наноносители с осмотически опосредованным высвобождением
EP2760390A4 (en) NASALINSATZ AND NASALKANÜLE, AND USE METHOD THEREFOR
EP2707379A4 (en) USE OF PURIFIED 2'-FUCOSYLLACTOSIS, 3-FUCOSYLLACTOSIS AND LACTODIFUCOTETRAOSE AS PREBIOTICS
WO2013046060A9 (en) Paper and methods of making paper
ZA201309264B (en) Controlled release nasal testosterone gels,methods and pre-filled multi-dose applicator systems for pernasal administration
WO2012158843A3 (en) Kinase inhibitors
EP2758622B8 (en) Adjustable fracturing head and manifold system
FR2978525B1 (fr) Vitrage multiple lumineux de meuble
WO2012122383A3 (en) Pi3 kinase inhibitors and uses thereof
FI20116192A (fi) Ponttiliitos, paalu ja paaluseinä
EP2985282A4 (en) Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives
SMT201600190B (it) Uso di streptococcus salivarius nel trattamento di infezioni croniche dell'apparato respiratorio
EE201100013A (et) Lhisolekute tekitamise meetod plokkjuhtimisega he- v?i mitmefaasilisele impedants-, kvaasiimpedants- ja transimpedants-tpi vaheldile
EP2536822A4 (en) MEDIA, KITS, SYSTEMS AND METHOD FOR MICROVERMING BAMBOO
BR112014001221A2 (pt) método e uso de histamina bacteriana
GB2522564B (en) Hard surface cleaners having cleaning heads with rotational assist, and associated systems, apparatuses, and methods
MX351189B (es) Inhibidor de alfa1-proteinasa para demorar el comienzo o progresión de exacerbaciones pulmonares.
PT2717883T (pt) Proteção contra disfunção de barreira endotelial através de inibição do gene relacionado com abl de tirosina quinase (arg)
EP2269994A4 (en) POLYMORPHES OF 4-ANILINOCHINAZOLINE DERIVATIVES, THEIR PREPARATION AND THEIR USES
EP3014548A4 (en) Methods and systems for redeeming and managing digital coupons
BR112013023575A2 (pt) “derivado de octaidrotienoquinolina, composição farmacêutica compreendendo o derivado, e uso destes”
BR112013012175A2 (pt) combinação, coadministração, uso e método
HK1185365A1 (en) Aqueous 1k coating system and method for improving the appearance of grained wood surfaces 1k
IL231820A0 (en) A method for reducing facial redness associated with the systematic use of phosphodiesterase type 5 inhibitors